RIPK1 and neoplasm: There is concrete evidence that the expression levels of key necroptosis mediators such as RIPK1 and RIPK3 may vary significantly among different tumor cell clones in the same tumors 51, 52, suggesting the variation of necroptosis susceptibility in heterogenous tumor cell populations may cause significant alteration in the RT responses.